Photoactive trans ammine/amine diazido platinum(IV) complexes

The synthesis and characterisation of eight new octahedral Pt^IV complexes of the type trans,trans,trans-[Pt(N₃)₂(OH)₂(NH₃)(Am)] where Am = methylamine (2), ethylamine (4), thiazole (6), 2-picoline (8), 3-picoline (10), 4-picoline (12), cyclohexylamine (14), and quinoline (16) are reported, including the X-ray crystal structures of complexes 2, 8, and 14 as well as that of two of the precursor Pt^II complexes (trans-[Pt(N₃)₂(NH₃)(methylamine)] (1) and trans-[Pt(N₃)₂(NH₃)(cyclohexylamine)] (13)). Irradiation with UVA light rapidly induces loss in intensity of the azide-to-Pt^IV charge-transfer bands and gives rise to photoreduction of platinum. These complexes have potential for use as photoactivated anticancer agents.     

Synthesis, characterization and cytotoxic properties of platinum(II) complexes containing the nucleosides adenosine and cytidine

Cytidine (cyt) and adenosine (ado) react with cis-[L₂Pt(μ-OH)]₂(NO₃)₂ (L = PMe₃, PPh₃) in various solvents to give the nucleoside complexes cis-[L₂Pt{cyt(− H),N³N⁴}]₃(NO₃)₃ (L = PMe₃, 1),cis-[L₂Pt{cyt(− H),N⁴}(cyt,N³)]NO₃ (L = PPh₃, 2), cis-[L₂Pt{ado(− H),N¹N⁶}]₂(NO₃)₂ (L = PMe₃, 3) and cis-[L₂Pt{ado(− H),N⁶N⁷}]NO₃ (L = PPh₃, 4). When the condensation reaction is carried out in solution of nitriles (RCN, R = Me, Ph) the amidine derivatives cis-[(PPh₃)₂PtNH=C(R){cyt(− 2H)}]NO₃ (R = Me, 5a; R = Ph, 5b) and cis-[(PPh₃)₂PtNH=C(R){ado(− 2H)}]NO₃ (R = Me, 6a: R = Ph, 6b) are quantitatively formed. The coordination mode of these nucleosides, characterized in solution by multinuclear NMR spectroscopy and mass spectrometry, is similar to that previously observed for the nucleobases 1-methylcytosine (1-MeCy) and 9-methyladenine (9-MeAd). The cytotoxic properties of the new complexes, and those of the nucleobase analogs, cis-[(PPh₃)₂PtNH=C(R){1-MeCy(− 2H)}]NO₃ (R = Me, 7a: R = Ph, 7b), cis-[(PPh₃)₂PtNH=C(R){9-MeAd(− 2H)}]NO₃ (R = Me, 8a: R = Ph, 8b) have been investigated in a wide panel of human cancer cells. Interestingly, whereas the Pt(II) nucleoside complexes (1-4) did not show appreciable cytotoxicity, the corresponding amidine derivatives (7a, 7b, 8a, 8b, 5b, and 6b) exhibited a significant in vitro antitumor activity.     

Platinum (II) and palladium (II) 1,3,5-triaza-7-phosphaadamantane (PTA) complexes as intramolecular hydroamination catalysts in aqueous and organic media

Complexes of the general formula cis-[MX₂(PTA)₂] (M = Pd, Pt; X = Cl, Br, I; PTA = 1,3,5-triaza-7-phosphaadamantane) were used to study the catalytic intramolecular hydroamination/cyclization of 4-pentyn-1-amine into 2-methyl-pyrroline in water, methanol, and dimethyl sulfoxide (DMSO). Kinetic data were measured via ¹H NMR under homogeneous conditions at 50 °C and showed the following trends in rate: (i) Fastest rates were observed in D₂O. (ii) The Pd complexes of this study produced faster rates than the Pt complexes. (iii) The identity of the halide had no effect on the catalytic rate. Cyclization by the catalytic precursor cis-[PdCl₂(PTA)₂] (4) in D₂O was zero-order in substrate and first-order in metal complex with ΔH^‡ = 20.0 ± 2.1 kcal/mol, ΔS^‡ = −7.4 ± 6.3 cal/mol K, and E_a = 20.6 ± 2.1 kcal/mol. The acetylide complex, trans-[Pt(CC(CH₂)₃NH₂)₂(PTA)₂] (6) precipitated from a catalytic mixture involving cis-[PtBr₂(PTA)₂] (2). Spectroscopic and kinetic studies indicated that 6 and its cis analog, 7, were the predominant species in solution and that they were both active catalysts for the cyclization reaction. These data, in conjunction with the rate trends, indicated that the mechanism of the Pd(II) and Pt(II) catalyzed hydroamination of terminal alkynylamines in aqueous solution followed a unique mechanism with cyclization of an acetylenic-amine ligand being rate determining.     

Hydrogen-halide versus alkyl-halide oxidative addition in dimethyl platinum(II) complexes: Crystal structure of [PtBr2(bpy)]

Dimethyl platinum(II) complexes [PtMe₂(NN)] {NN = bu₂bpy (4,4′-di-tert-butyl-2,2′-bipyridine) (1a), bpy (2,2′-bipyridine) (1b), phen (1,10-phenanthroline) (1c)} reacted with commercial 3-bromo-1-propanol in the presence of 1,3-propylene oxide to afford cis, trans- [PtBrMe₂{(CH₂)₃OH}(NN)] (NN = bu₂bpy (2a), bpy (2b), phen (2c)). On the other hand, [PtMe₂(NN)] (1a)-(1b) reacted with the trace of HBr in commercial 3-bromo-1-propanol to give [PtBr₂(NN)] (NN = bu₂bpy (3a), bpy (3b)). The reaction pathways were monitored by ¹H NMR at various temperatures. Treatment of 1a-1b with a large excess of 3-bromo-1-propanol at −80 °C gave the corresponding methyl(hydrido)platinum(IV) complexes [PtBr(H)Me₂(NN)] (NN = bu₂bpy (4a), bpy (4b)) via the oxidative addition of dimethyl platinum(II) complexes with HBr. The complexes [PtBr(H)Me₂(NN)] decomposed by reductive elimination of methane above −20 °C for bu₂bpy and from −20 to 0 °C for bpy analogue to give methane and platinum(II) complexes [PtBrMe(NN)] (5a)-(5b) and then decomposed at about 0 °C to yield [PtBr₂(NN)] and methane. When the reactions were performed at a molar ratio of Pt:RX/1:10, the corresponding complexes [PtBrMe(NN)] (5a)-(5b) were also obtained. The crystal structure of the complex 3b shows that platinum adopts square planar geometry with a twofold axis through the platinum atom. The Pt…Pt distance (5.164 Å) is considerably larger than the interplanar spacing (3.400 Å) and there is no platinum-platinum interaction.     

Antisymbiosis. Preferential coordination of anionic oxygen versus neutral sulfur donor atoms of methylsulfanyl- or methylsulfinyl-acetato, 2-benzoato and 2-phenolato to the cis-Pt(PPh3)2 and Pt(dppe) residues

The interaction of an excess of the title ligands L⁻ with the cis-Pt(phos)₂ moieties gives compounds a-bcis-[Pt(L-O)₂(phos)₂] (a, phos = P(Ph)₃; b, phos = 1/2 dppe), in which O- is preferred to S-coordination. Such preference is confirmed by the fact that the same products are obtained by reaction of excess of L⁻ with the previously reported a-d complexes [Pt(L-O,S)(phos)₂]⁺, (c, phos = PPh₃, d, phos = 1/2 dppe), for which chelate ring opening occurs with rupture of Pt-S rather than Pt-O bonds. Compound a can be obtained also by oxidative addition of HL to [Pt(PPh₃)₃]. The Pt-O bonds in compounds a-d are stable towards substitution by Me₂SO, pyridine and tetramethylthiourea. Substitution of L’s occurs with N,N′-diethyldithiocarbamate, which forms a very stable chelate with Pt(II). Thiourea and N,N′-dimethylthiourea also react, because they give rise to cyclometallated products [Pt(phos)₂(NRC(S)NHR)]⁺ (R = H, CH₃), with one ionised thioamido group, as revealed by an X-ray investigation of [Pt(PPh₃)₂(NHC(S)NH₂)]⁺. The preference of O versus S coordination, as well as the stability of the Pt-O bonds, are discussed in terms of antisymbiosis.     

Synthesis of [SnPh2(SR)2] SR = SC6F4-4-H, SC6F5: Reactivity towards group 10 transition metal complexes

The organometallic tin(IV) complexes [SnPh₂(SR^F)₂] SR^F = ⁻SC₆F₄-4-H (1), ⁻SC₆F₅ (2), were synthesized and their reactivity with [MCl₂(PPh₃)₂] M = Ni, Pd and Pt explored. Thus, transmetallation products were obtained affording polymeric [Ni(SR^F)(μ-SR^F)]_n, monomeric cis-[Pt(PPh₃)₂(SC₆F₄-4-H)₂] (3) and cis-[Pt(PPh₃)₂(SC₆F₅)₂] (4) and dimeric species [Pd(PPh₃)(SC₆F₄-4-H)(μ-SC₆F₄-4-H)]₂ (5) and [Pd(PPh₃)(SC₆F₅)(μ-SC₆F₅)]₂ (6) for Ni, Pt and Pd, respectively. The crystal structures of complexes 1, 2, 3, 4 and 6 were determined.     

Copper(II) complexes derived from tripodal tris[(2-ethyl-(1-pyrazolyl)]amine

Three mono-nuclear copper(II) complexes [Cu(tepza)X]ClO₄ (X = Cl, 1; X = NCS, 2; X = dca, 3) and two dinuclear bridging complexes [Cu₂(tepza)₂(μ-C₄O₄)](ClO₄)₂·H₂O(4) and [Cu₂(tepza)₂(μ-C₅O₅)](ClO₄)₂(5) where tepza = tris[2-ethyl(1-pyrazolyl)]amine, dca = dicyanamide, C₄O₄²⁻ = 3,4-dihydroxycyclobut-3-ene-1,2-dionate (squarate dianion) and C₅O₅²⁻ = 4,5-dihydroxycyclopent-4-ene-1,2,3-trionate (croconate dianion) were synthesized and structurally characterized by IR and UV-Vis spectroscopy as well as by single X-ray crystallography. In the solid state, the geometry of copper(II) centers in these complexes are as follows: close to SP in 2, distorted TBP in 3, predominant SP in 4, and distorted octahedral in 5, whereas in solution distorted SP geometry was generally found. The squarato and the croconato dianions in complexes 4 and 5 are bridging the two copper(II) centers in cis-bis-monodentate and bis-bidentate bonding modes, respectively. Magnetic susceptibility measurements at variable temperatures (2-300 K) reveal the weak antiferromagnetic coupling in the two bridging dinuclear complexes 4 (J = −24.9 cm⁻¹) and 5 (J = −3.1 cm⁻¹).     

Synthesis and reactivity of osmium (VI) nitrido complexes containing pyridine-carboxylato ligands

A series of osmium(VI) nitrido complexes containing pyridine-carboxylato ligands Os^VI(N)(L)₂X (L = pyridine-2carboxylate (1), 2-quinaldinate (2) and X = Cl (a), Br (1b and 2c) or CH₃O (2b)) and [Os^VI(N)(L)X₃]⁻ (L = pyridine-2,6-dicarboxylate (3) and X = Cl (a) or Br (b)) have been synthesised. Complexes 1 and 2 are electrophilic and react readily with various nucleophiles such as phosphine, sulfide and azide. Reaction of Os^VI(N)(L)₂X (1 and 2) with triphenylphosphine produces the osmium(IV) phosphiniminato complexes Os^VI(NPPh₃)(L)₂X (4 and 5). The kinetics of nitrogen atom transfer from the complexes Os^VI(N)(L)₂Br (2c) (L = 2-quinaldinate) with triphenylphosphine have been studied in CH₃CN at 25.0 °C by stopped-flow spectrophotometric method. The following rate law is obtained: −d[Os(VI)]/dt = k₂[Os(VI)][PPh₃]. Os^VI(N)(L)₂Cl (L = 2-quinaldinate) (2a) reacts also with [PPN](N₃) to give an osmium(III) dichloro complex, trans-[PPN][Os^III(L)₂Cl₂] (6). Reaction of Os^VI(N)(L)₂Cl (L = 2-quinaldinate) (2a) with lithium sulfide produces an osmium(II) thionitrosyl complex Os^II(NS)(L)₂Cl (7). These complexes have been structurally characterised by X-ray crystallography.     

Stereosensitive formation and interconversion of sulfur-bridged cobalt(III)-mercury(II) polynuclear complexes with d- and/or l-penicillaminates

The reaction of trans(N)-[Co(d-pen)₂]⁻ (pen = penicillaminate) with HgCl₂ or HgBr₂ in the molar ratios of 1:1 gave the sulfur-bridged heterodinuclear complex, [HgX(OH₂){Co(d-pen)₂}] (X = Cl (1a) or Br (1b)). A similar reaction in the ratio of 2:1 produced the trinuclear complex, [Hg{Co(d-pen)₂}₂] (1c). The enantiomers of 1a and 1c, [HgCl(OH₂){Co(l-pen)₂}] (1a′) and [Hg{Co(l-pen)₂}₂] (1c′), were also obtained by using trans(N)-[Co(l-pen)₂]⁻ instead of trans(N)-[Co(d-pen)₂]⁻. Further, the reaction of cis · cis · cis-[Co(d-pen)(l-pen)]⁻ with HgCl₂ in the molar ratio of 1:1 resulted in the formation of [HgCl(OH₂){Co(d-pen)(l-pen)}] (2a). During the formations of the above six complexes, 1a, 1b, 1c, 1a′, 1c′, and 2a, the octahedral Co(III) units retain their configurations. On the other hand, the reaction of cis · cis · cis-[Co(d-pen)(l-pen)]⁻ with HgCl₂ in the molar ratio of 2:1 gave not [Hg{Co(d-pen)(l-pen}₂] but [Hg{Co(d-pen)₂}{Co(l-pen)₂}] (2c), accompanied by the ligand-exchange on the terminal Co(III) units. The X-ray crystal structural analyses show that the central Hg(II) atom in 1c takes a considerably distorted tetrahedral geometry, whereas that in 2c is of an ideal tetrahedron. The interconversion between the complexes is also examined. The electronic absorption, CD, and NMR spectral behavior of the complexes is discussed in relation to the crystal structures of 1c and 2c.     

Hybrid scorpionate/cyclopentadienyl titanium and zirconium complexes with alkoxide and imido ligands

The reactivity of hybrid scorpionate/cyclopentadienyl ligand-containing trichloride zirconium complexes [ZrCl₃(bpzcp)] (1) [bpzcp = 2,2-bis(3,5-dimethylpyrazol-1-yl)-1,1-diphenylethylcyclopentadienyl] and [ZrCl₃(bpztcp)] (2) [bpztcp = 2,2-bis(3,5-dimethylpyrazol-1-yl)-1-tert-butylethylcyclopentadienyl] toward several lithium alkoxides has been carried out. Thus, alkoxide-containing complexes [ZrCl₂(OR)(bpzcp)] (R = Me, 3; Et, 4; ⁱPr, 5; (R)-2-Bu, 6), [ZrCl₂(OR)(bpztcp)] (R = Me, 7; Et, 8; ⁱPr, 9; (R)-2-Bu, 10) and [Zr(OR)₃(bpztcp)] (R = Et, 11; ⁱPr, 12) were prepared by deprotonation of the appropriate alcohol group with BuⁿLi followed by reaction with 1 or 2. In addition, the imido-complex [Ti(N^tBu)Cl(bpztcp)(py)] (13) were also prepared. The structures of these complexes have been proposed on basis of spectroscopic and DFT methods.     

Synthesis and structures of platinum(II) complexes with 5-ferrocenylpyrimidine

Reaction of platinum(II) salts with 5-ferrocenylpyrimidine (FcPM) afforded cis-[Pt(NH₃)₂(FcPM)₂](PF₆)₂ (1), trans-[Pt(NH₃)₂(FcPM)₂](PF₆)₂ (2), cis-[PtCl₂(FcPM)₂] (3), and cis-[PtCl₂(DMSO)(FcPM)] (4): their spectroscopic and electrochemical properties were investigated. Complexes 1 and 2 were structurally characterized by X-ray crystallography.     

Synthesis and characterisation of palladium(II) and platinum(II) compounds containing pyrazole-derived ligands: crystal structure of [PdCl2(HL)] (HL = 3-phenyl-5-(2-pyridyl)pyrazole)

Reaction of the ligands 3-phenyl-5-(2-pyridyl)pyrazole (HL¹), 3,5-bis(2-pyridyl)pyrazole (HL²), 3-methyl-5-(2-pyridyl)pyrazole (HL³) and 3-methyl-5-phenylpyrazole (HL⁴) with [MCl₂(CH₃CN)₂] (M = Pd(II), Pt(II)) or [PdCl₂(cod)] gives complexes with stoichiometry [PdCl₂(HL)₂] (HL = HL¹, HL², HL³), [Pt(L)₂] (L = L¹, L², L³) and [MCl₂(HL⁴)₂] (M = Pd(II), Pt(II)). The new complexes were characterised by elemental analyses, conductivity measurements, infrared and ¹H NMR spectroscopies. The crystal and molecular structure of [PdCl₂(HL¹)] was resolved by X-ray diffraction, and consists of monomeric cis-[PdCl₂(HL¹)] molecules. The palladium centre has a typical square planar geometry, with a slight tetrahedral distortion. The tetra-coordinated metal atom is bonded to one pyridine nitrogen, one pyrazolic nitrogen and two chloro ligands in a cis disposition. The ligand HL¹ is not completely planar.     

Interaction of Pt(II) and Pd(II) complexes of terpyridine with 1-methylazoles: A combined experimental and density functional study

The synthesis and characterization of several complexes of the composition [{M(terpy)}_n(L)](ClO₄)_m (M = Pt, Pd; L = 1-methylimidazole, 1-methyltetrazole, 1-methyltetrazolate; terpy = 2,2′:6′,2″-terpyridine; n = 1, 2; m = 1, 2, 3) is reported and their applicability in terms of a metal-mediated base pair investigated. Reaction of [M(terpy)(H₂O)]²⁺ with 1-methylimidazole leads to [M(terpy)(1-methylimidazole)](ClO₄)₂ (1: M = Pt; 2: M = Pd). The analogous reaction of [Pt(terpy)(H₂O)]²⁺ with 1-methyltetrazole leads to the organometallic compound [Pt(terpy)(1-methyltetrazolate)]ClO₄ (3) in which the aromatic tetrazole proton has been substituted by the platinum moiety. For both platinum(II) and palladium(II), doubly metalated complexes [{M(terpy)}₂(1-methyltetrazolate)](ClO₄)₃ (4: M = Pt; 5: M = Pd) can also be obtained depending on the reaction conditions. In the latter two compounds, the [M(terpy)]²⁺ moieties are coordinated via C5 and N4. X-ray crystal structures of 1, 2, and 3 are reported. In addition, DFT calculations have been carried out to determine the energy difference between fully planar [Pd(mterpy)(L)]²⁺ complexes Ip-IVp (mterpy = 4′-methyl-2,2′:6′,2″-terpyridine; L = 1-methylimidazole-N3 (I), 1-methyl-1,2,4-triazole-N4 (II), 1-methyltetrazole-N3 (III), or 3-methylpyridine-N1 (IV)) and the respective geometry-optimized structures Io-IVo. Whereas this energy difference is larger than 70 kJ mol⁻¹ for compounds I, II, and IV, it amounts to only 0.8 kJ mol⁻¹ for the tetrazole-containing complex III, which is stabilized by two intramolecular C-H?N hydrogen bonds. Of all complexes under investigation, only the terpyridine-metal ion-tetrazole system with N3-coordinated tetrazole appears to be suited for an application in terms of a metal-mediated base pair in a metal-modified oligonucleotide.     

Reaction of [MCl2(CH3CN)2] (M = Pd(II), Pt(II)) compounds with N1-alkylpyridylpyrazole-derived ligands

Palladium(II) and platinum(II) complexes with N-alkylpyridylpyrazole-derived ligands, 2-(1-ethyl-5-phenyl-1H-pyrazol-3-yl)pyridine (L¹) and 2-(1-octyl-5-phenyl-1H-pyrazol-3-yl)pyridine (L²), cis-[MCl₂(L)] (M = Pd(II), Pt(II)), have been synthesised. Treatment of [PdCl₂(L)] (L = L¹, L²) with excess of ligand (L¹, L²), pyridine (py) or triphenylphosphine (PPh₃) in the presence of AgBF₄ and NaBPh₄ produced the following complexes: [Pd(L)₂](BPh₄)₂, [Pd(L)(py)₂](BPh₄)₂ and [Pd(L)(PPh₃)₂](BPh₄)₂. All complexes have been characterised by elemental analyses, conductivity, IR and NMR spectroscopies. The crystal structures of cis-[PdCl₂(L²)] (2) and cis-[PtCl₂(L¹)] (3) were determined by a single crystal X-ray diffraction method. In both complexes, the metal atom is coordinated by one pyrazole nitrogen, one pyridine nitrogen and two chlorine atoms in a distorted square-planar geometry. In complex 3, π-π stacking between pairs of molecules is observed.     

Synthesis and characterisation of new N1-alkyl-3,5-dipyridylpyrazole derived ligands. Study of their reactivity with Pd(II) and Pt(II)

Two new pyrazole-derived ligands, 1-ethyl-3,5-bis(2-pyridyl)pyrazole (L¹) and 1-octyl-3,5-bis(2-pyridyl)pyrazole (L²), both containing alkyl groups at position 1 were prepared by reaction between 3,5-bis(2-pyridyl) pyrazole and the appropriate bromoalkane in toluene using sodium ethoxide as base.The reaction between L¹, L² and [MCl₂(CH₃CN)₂] (M = Pd(II), Pt(II)) resulted in the formation complexes of formula [MCl₂(L)] (M = Pd(II), L = L¹ (1); M = Pd(II), L = L² (2); M = Pt(II), L = L¹ (3); M = Pt(II), L = L² (4)). These complexes were characterised by elemental analyses, conductivity measurements, infrared, ¹H, ¹³C{¹H} NMR and HMQC spectroscopies. The X-ray structure of the complex [PtCl₂(L²)] (4) was determined. In this complex, Npyridine and Npyrazole donor atoms coordinate the ligand to the metal, which complete its coordination with two chloro ligands in a cis disposition.     

Synthesis, X-ray crystal structures and properties of complex salts and sterically crowded heteroleptic complexes of group 10 metal ions with aromatic sulfonyl dithiocarbimates and triphenylphosphine ligand

Two new complex salts of the form (Bu₄N)₂[Ni(L)₂] (1) and (Ph₄P)₂[Ni(L)₂] (2) and four heteroleptic complexes cis-M(PPh₃)₂(L) [M = Ni(II) (3), Pd(II) (4), L = 4-CH₃OC₆H₄SO₂NCS₂] and cis-M(PPh₃)₂(L′) [ M = Pd(II) (5), Pt(II) (6), L′ = C₆H₅SO₂NCS₂] were prepared and characterized by elemental analyses, IR, ¹H, ¹³C and ³¹P NMR and UV-Vis spectra, solution and solid phase conductivity measurements and X-ray crystallography. A minor product trans-Pd(PPh₃)₂(SH)₂, 4a was also obtained with the synthesis of 4. The NiS₄ and MP₂S₂ core in the complex salts and heteroleptic complexes are in the distorted square-plane whereas in the trans complex, 4a the centrosymmetric PdS₂P₂ core is perforce square planar. X-ray crystallography revealed the proximity of the ortho phenyl proton of the PPh₃ ligand to Pd(II) showing rare intramolecular C-H?Pd anagostic binding interactions in the palladium cis-5 and trans-4a complexes. The complex salts with σ_rt values ∼10⁻⁵ S cm⁻¹ show semi-conductor behaviors. The palladium and platinum complexes show photoluminescence properties in solution at room temperature.     

Hydrogen bonding patterns in pyrazole Pt(II- and IV) chloride complexes

The solid-state packing arrays of the platinum(II) trans- and cis-[PtCl₂(PzH)₂] (1 and 2) and platinum(IV) trans- and cis-[PtCl₄(PzH)₂] (3 and 4) complexes have been examined and the occurrence of N-H ? Cl hydrogen-bonding associations in those structures has been discussed. Although different packing motifs are observed, in all cases molecules are interacting mostly via NH ? Cl and CH ? Cl associations. The square planar 1 and 2 form stacked arrays of PtCl₂(PzH)₂, which are supported by NH ? Cl and CH ? Cl hydrogen bonding. The isomeric structure of the complexes and orientation of the PzH rings determine NH ? Cl bonding mode (intermolecular or intramolecular) and also the extent of the platinum-platinum interaction. The synthetic procedures for the preparation of 1-4 along with elemental and X-ray analyses, TG/DTA, FAB⁺-MS, IR, and ¹H and ¹³C{¹H} NMR data are also given in this article.     

Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity

[Pt(L)₂(ox)] (1), [Pt(2-OMeL)₂(ox)] (2), [Pt(3-OMeL)₂(ox)] (3), [Pt(2,3-diOMeL)₂(ox)] (4), [Pt(2,4-diOMeL)₂(ox)] (5), [Pt(3,4-diOMeL)₂(ox)] (6) and [Pt(3,5-diOMeL)₂(ox)]·4H₂O (7) platinum(II) oxalato (ox) complexes were synthesized using the reaction of potassium bis(oxalato)platinate(II) dihydrate with 2-chloro-N6-(benzyl)-9-isopropyladenine or its benzyl-substituted analogues (nL). The complexes 1-7, which represent the first platinum(II) oxalato complexes involving adenine-based ligands, were fully characterized by various physical methods including multinuclear and two dimensional NMR spectroscopy. A single-crystal X-ray analysis of [Pt(2,4-diOMeL)₂(ox)]·2DMF (5·2DMF; DMF = N,N′-dimethylformamide), proved the slightly distorted square-planar geometry in the vicinity of the Pt(II) ion with one bidentate-coordinated oxalate dianion and two adenine derivatives (nL) coordinated to the Pt(II) centre through the N7 atom of an adenine moiety, thereby giving a PtN₂O₂ donor set. In vitro cytotoxicity of the prepared complexes was tested by an MTT assay against osteosarcoma (HOS) and breast adenocarcinoma (MCF7) human cancer cell lines. The best results were achieved for the complexes 2 and 5 in the case of both cell lines, whose IC₅₀ values equalled 3.6 ± 1.0, and 4.3 ± 2.1 μM (for 2), and 5.4 ± 3.8, and 3.6 ± 2.1 μM (for 5), respectively. The IC₅₀ equals 9.2 ± 1.5 μM against MCF7 cells in the case of 1. The in vitro cytotoxicity of the mentioned complexes significantly exceeded commercially used platinum-based anticancer drugs cisplatin (34.2 ± 6.4 μM and 19.6 ± 4.3 μM) and oxaliplatin (> 50.0 μM for both cancer cell lines).     

Influence of the phosphine arrangement on the reactivity of palladium(II) and platinum(II) polyphosphine complexes with copper(I) chloride

The distorted square-planar complexes [Pd(PNHP)Cl]Cl (1) (PNHP = bis[2-(diphenylphosphino)ethyl]amine), [M(P₃)Cl]Cl [P₃ = bis[2-(diphenylphosphino)ethyl]phenylphosphine; M = Pd (2), Pt (3)] and [Pt(NP₃)Cl]Cl (5) (NP₃ = tris[2-(diphenylphosphino)ethyl]amine), coexisting in the later case with a square-pyramidal arrangement, react with one equivalent of CuCl to give the mononuclear heteroionic systems [M(L)Cl](CuCl₂) [L = PNHP, M = Pd (1a); L = P₃, M = Pd (2a), Pt (3a); L = NP₃, M = Pt (5a)]. The crystal structure of 3a confirms that Pt(II) retains the distorted square-planar geometry of 3 in the cation with P₃ acting as tridentate chelating ligand, the central P atom being trans to one chloride. The counter anion is a nearly linear dichlorocuprate(I) ion. However, the five-coordinate complexes [Pd(NP₃)Cl]Cl (4), [M(PP₃)Cl]Cl (M = Pd (6), Pt (7); PP₃ = tris[2-(diphenylphosphino)ethyl] phosphine) containing three fused five-membered chelate rings undergo a ring-opening by interaction with one (4, 6, 7) and two (6, 7) equivalents of CuCl with formation of neutral MCu(L)Cl₃ [L = NP₃, M = Pd (4a); L = PP₃, M = Pd (6a), Pt (7a)] and ionic [MCu(PP₃)Cl₂](CuCl₂) [M = Pd (6b), Pt (7b)] compounds, respectively. The heteronuclear systems were shown by ³¹P NMR to have structures where the phosphines are acting as tridentate chelating ligands to M(II) and monodentate bridging to Cu(I). Further additions of CuCl to the neutral species 6a and 7a in a 1:1 ratio resulted in the achievement of the ionic complexes 6b and 7b with ions as counter anions. It was demonstrated that the formation of heterobimetallic or just mononuclear mixed salt complexes was clearly influenced by the polyphosphine arrangement with the tripodal ligands giving the former compounds. However, complexes [M(NP₃)Cl]Cl constitute one exception and the type of reaction undergone versus CuCl is a function of the d⁸ metal centre.     

New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro

The reaction of aqueous cis-[Pt(NH₃)₂(H₂O)₂](NO₃)₂ with Na⁺HMEL⁻ (H₂MEL, meloxicam, 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide), and Na⁺HISO⁻ (H₂ISO, isoxicam, 4-hydroxy-2-methyl-N-(5-methylisoxazol-3-yl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide) at pH 7 produced micro-crystalline cis-[Pt(NH₃)₂(N^1′-HMEL)₂], 5 and cis-[Pt(NH₃)₂(N^1′-HISO)₂], 6. The X-ray diffraction structure of 5 shows two HMEL⁻ anions donating through the thiazole nitrogen atoms and adopting a head-to-tail (HT) conformation. The ¹H NMR spectrum for 5 from DMSO-d₆ shows inertness of the complex up to at least 24 h. Delivery studies for 5 and 6 from vinyl hydrogel based on l-phenylalanine (pH 6.5, 25 °C) show that concentrations of complexes ranging between 2.5 and 5 μM can be reached after a day. Compounds 5 and 6 show strong anti-proliferative effects on CH1 cells (ovarian carcinoma, human) in vitro, IC₅₀ values being 0.60 and 0.37 μM, respectively (0.16 μM for reference, cis-diamminodichloridoplatinum(II), cisplatin). ESI-MS measurements clearly documented that both 5 and 6 form adducts with the three model proteins ubiquitin (UBI), cytochrome c (CYT C) and superoxide dismutase (SOD), the HISO⁻ complex being significantly more effective than the HMEL⁻ one. Density functional methods help in finding rationale for the easiest dissociation of Pt-H₂ISO/HISO bonds when compared to the Pt-N^1′-H₂MEL/N^1′-HMEL linkages.